Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephanie Royer

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid TumorsAnthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.
Journal for Immunotherapy of Cancer|June 21, 2018
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsAsha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast CancerKomal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b studyPhilippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian CancerDavid E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I StudyAdrian G Sacher, Wilson H Miller, Manish R Patel, et al.
Nature Medicine|December 5, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trialJayesh Desai, Guzman Alonso, Se Hyun Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid TumorsAnthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.
Journal for Immunotherapy of Cancer|June 21, 2018
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumorsAsha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast CancerKomal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b studyPhilippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2019
Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian CancerDavid E Gerber, Jeffrey R Infante, Michael S Gordon, et al.
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I StudyAdrian G Sacher, Wilson H Miller, Manish R Patel, et al.
Nature Medicine|December 5, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trialJayesh Desai, Guzman Alonso, Se Hyun Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.
Pageof 2